Hepatitis C virus: Morphogenesis, infection and therapy

doi:10.4254/wjh.v10.i2.186

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (30479)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-4) series.

Item

Count

PDF

2927

WORD

516

HTML

23651

Figures (1-10)

615

Tables (1-4)

180

Sum=27889

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1249

Download

1341

Sum=2590

Feb 27, 2018 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (99)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Feb 27, 2018; 10(2): 186-212
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186

Table 4 Selected directly acting antiviral agents and host targeting agents whose development has been stopped or temporarily halted[63]

Drugs name Company Target/Active site
NS3 /4A protease inhibitors
Ciluprevir BILN 2061	Boehringer Ingelheim	Active site/macrocyclic
Narlaprevir (SCH900518)	Schering-Plough	Active site/linear
PHX1766	Pheromix	Active site
Danoprevir (R7227)	Roche/InterMune	Active site/macrocyclic
Faldaprevir (BI201335)	Boehringer Ingelheim	Active site/linear
Telaprevir (VX-950)	Vertex	Withdrawn
Boceprevir (SCH503034)	Merck	Withdrawn
Nucleoside analogue NS5B polymerase inhibitors (NI)
Valopicitabine (NM283)	Idenix/Novartis	Active site
R1626	Roche	Active site
Mericitabine (R7128)	Roche/Pharmasset	Active site
GS-938	Gilead	Active site
IDX184	Idenix	Active site
Non-nucleoside NS5B polymerase inhibitors (NNI)
BILB 1941	Boehringer Ingelheim	NNI site 1/thumb
MK-3281	Merck	NNI site 1/thumb 1
VX-759	Vertex	NNI site 2/thumb 2
VX-222	Vertex	NNI site 2/thumb 2
VX-916	Vertex	NNI site 2/thumb 2
ABT-072	AbbVie	NNI site 3/palm 1
HCV-796	ViroPharma/Wyeth	NNI site 4/palm 2
Filibuvir (PF-00868554)	Pfizer	NNI site 2/thumb 2
IDX375	Idenix	NNI site 4/palm 2
Tegobuvir (GS-9190)	Gilead	NNI site 4/palm 2
GS-9669	Gilead	NNI site 3/palm 1
Deleobuvir	Böhringer	NNI site 3/palm 1
Host targeting agents
NIM811	Novartis	Cyclophilin inhibitor
Alisporivir (Debio-025)	Novartis	Cyclophilin inhibitor

Citation: Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212
URL: https://www.wjgnet.com/1948-5182/full/v10/i2/186.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i2.186